LIXTW (Lixte Biotechnology Holdings) LT-Debt-to-Total-Asset: 0.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LIXTW Lixte Biotechnology Holdings Inc LIXTW
34 GF Score
Price $0.02
! 1 Warning Sign
View Full Analysis

What is Lixte Biotechnology Holdings LT-Debt-to-Total-Asset?

Lixte Biotechnology Holdings LIXTW +4.74% 34 LT-Debt-to-Total-Asset is 0.01 as of Jun. 2026. GuruFocus rates LIXTW with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lixte Biotechnology Holdings's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.01.

Lixte Biotechnology Holdings's long-term debt to total assets ratio increased from Jun. 2025 (0.00) to Jun. 2026 (0.01). It may suggest that Lixte Biotechnology Holdings is progressively becoming more dependent on debt to grow their business.

Lixte Biotechnology Holdings  (NAS:LIXTW) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Related Terms

Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lixte Biotechnology Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.03

Lixte Biotechnology Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.03 0.04 0.01
LIXTW
34GF Score
Lixte Biotechnology Holdings Inc LIXTW
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lixte Biotechnology Holdings LT-Debt-to-Total-Asset Calculation

Lixte Biotechnology Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.439/12.734
=

Lixte Biotechnology Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=0.161/26.649
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Lixte Biotechnology Holdings (LIXTW) has a LT-Debt-to-Total-Asset of 0.01 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lixte Biotechnology Holdings and its competitors.
Is Lixte Biotechnology Holdings' LT-Debt-to-Total-Asset too high?
Lixte Biotechnology Holdings' current LT-Debt-to-Total-Asset is 0.01. Overall, Lixte Biotechnology Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Lixte Biotechnology Holdings' LT-Debt-to-Total-Asset compare to CBAT and TGEN?
Lixte Biotechnology Holdings' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for an Industrial Products company?
A good LT-Debt-to-Total-Asset depends on the Industrial Products industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lixte Biotechnology Holdings and its competitors. Lixte Biotechnology Holdings's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lixte Biotechnology Holdings stock overvalued right now?
Lixte Biotechnology Holdings (LIXTW) has a current LT-Debt-to-Total-Asset of 0.01. The current LT-Debt-to-Total-Asset is 0.01. Lixte Biotechnology Holdings' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lixte Biotechnology Holdings (LIXTW), the current LT-Debt-to-Total-Asset is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lixte Biotechnology Holdings Business Description

Other Exchanges LIXT:USA
Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
34GF Score

Get the complete analysis for LIXTW

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price